| Title | The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC) |
| Authors | Liu, Liang Xiang, Jinfeng Chen, Rufu Fu, Deliang Hong, Defei Hao, Jihui Li, Yixiong Li, Jiangtao Li, Shengping Mou, Yiping Mai, Gang Ni, Quanxing Peng, Li Qin, Renyi Qian, Hongang Shao, Chenghao Sun, Bei Sun, Yongwei Tao, Min Tian, Bole Wang, Hongxia Wang, Jian Wang, Liwei Wang, Wei Wang, Weilin Zhang, Jun Zhao, Gang Zhou, Jun Yu, Xianjun |
| Affiliation | Fudan Univ, Shanghai Canc Ctr, Dept Pancreat Surg, 270 DongAn Rd, Shanghai 200032, Peoples R China. Fudan Univ, Shanghai Med Coll, Dept Oncol, 270 DongAn Rd, Shanghai 200032, Peoples R China. Fudan Univ, Pancreat Canc Inst, 270 DongAn Rd, Shanghai 200032, Peoples R China. Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Pancreaticobiliary Surg, Guangzhou 510275, Guangdong, Peoples R China. Fudan Univ, Huashan Hosp, Shanghai Med Coll, Pancreat Dis Inst,Dept Pancreat Surg, 270 DongAn Rd, Shanghai 200032, Peoples R China. Zhejiang Prov Peoples Hosp, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Zhejiang, Peoples R China. Tianjin Med Univ, Canc Inst & Hosp, Dept Pancreat Canc, Tianjin, Peoples R China. Cent S Univ, Xiangya Hosp, Dept Pancreatic Bililary Surg, Changsha, Hunan, Peoples R China. Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Surg, Hangzhou 310003, Zhejiang, Peoples R China. Sun Yat Sen Univ, Ctr Canc, Dept Hepatobiliary Oncol, Guangzhou 510275, Guangdong, Peoples R China. Zhejiang Prov Peoples Hosp, Dept Gastroenterol & Pancreat Surg, Hangzhou, Zhejiang, Peoples R China. Peoples Hosp Deyang, Dept Hepatobiliopancreat Surg, Deyang, Peoples R China. Hebei Med Univ, Hosp 4, Dept Hepatopancreatobiliary Surg, Shijiazhuang, Peoples R China. Huazhong Univ Sci & Technol, Affiliated Tongji Hosp, Tongji Med Coll, Dept Biliary Pancreat Surg, Wuhan 430074, Peoples R China. Peking Univ, Canc Hosp & Inst, Dept Hepatopancreatobiliary Surg, Beijing 100871, Peoples R China. Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Pancreat Biliary Surg, Shanghai, Peoples R China. Harbin Med Univ, Affiliated Hosp 1, Dept Pancreat & Biliary Surg, Harbin, Heilongjiang, Peoples R China. Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Biliary Pancreat Surg, Shanghai 200030, Peoples R China. Soochow Univ, Hosp 1, Dept Med Oncol, Suzhou, Peoples R China. Sichuan Univ, West China Hosp, Dept Hepatobiliarypancreat Surg, Chengdu 610064, Peoples R China. Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Med Oncol, Shanghai 200030, Peoples R China. Fudan Univ, Shanghai Peoples Hosp 1, Dept Med Oncol, 270 DongAn Rd, Shanghai 200032, Peoples R China. Fudan Univ, Huadong Hosp, Dept Surg, 270 DongAn Rd, Shanghai 200032, Peoples R China. Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Hangzhou 310003, Zhejiang, Peoples R China. Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Pancreat Dis Inst, Wuhan 430074, Hubei, Peoples R China. Peking Univ, Sch Oncolocy, Beijing Inst Canc Res, Dept Med Oncol, Beijing 100871, Peoples R China. Fudan Univ, Shanghai Canc Ctr, Dept Pancreat Surg, 270 DongAn Rd, Shanghai 200032, Peoples R China. Yu, XJ (reprint author), Fudan Univ, Shanghai Med Coll, Dept Oncol, 270 DongAn Rd, Shanghai 200032, Peoples R China. Yu, XJ (reprint author), Fudan Univ, Pancreat Canc Inst, 270 DongAn Rd, Shanghai 200032, Peoples R China. |
| Keywords | pancreatic cancer cancer antigen 125 mucin 16 diagnosis predictive potency prognosis SERUM TUMOR-MARKERS NEOADJUVANT CHEMOTHERAPY GASTRIC-CANCER DIFFERENTIAL-DIAGNOSIS OVARIAN-CANCER DUCTAL ADENOCARCINOMA F-18-FDG PET/CT OCULAR SURFACE 125 EXPRESSION CA125 |
| Issue Date | 2016 |
| Publisher | INTERNATIONAL JOURNAL OF ONCOLOGY |
| Citation | INTERNATIONAL JOURNAL OF ONCOLOGY.2016,48,(3),900-907. |
| Abstract | The prognosis for pancreatic cancer (PC) is poor; however, the timely and accurate treatment of this disease will significantly improve prognosis. Serum biomarkers involve noninvasive tests that facilitate the early detection of tumors, predict outcomes and assess responses to therapy, so that the patient can be continuously monitored and receive the most appropriate therapy. Studies have reported that cancer antigen (CA) 125 [also known as mucin 16 (MUC16)] has functional significance in the tumorigenic, metastatic and drug resistant properties of PC. Our aim was to use this biomarker in the diagnosis, detection of metastasis, prognosis and in the monitoring of the treatment effects of PC. Members of the Chinese Study Group for Pancreatic Cancer (CSPAC) reviewed the literature on CA125/MUC16 and developed an objective consensus on the clinical utility of CA125/MUC16 for PC. They confirmed the role of CA125/MUC16 in tumorigenesis and the progression of PC, and recommended monitoring CA125/MUC16 levels in all aspects of the diagnosis and treatment of PC, particularly those that involve the monitoring of treatments. In addition, they suggested that the combination of other biomarkers and imaging techniques, together with CA125/MUC16, would improve the accuracy of the clinical decision-making process, thereby facilitating the optimization of treatment strategies. Periodic clinical updates of the use of CA125/MUC16 have been established, which are important for further analyses and comparisons of clinical results from affiliates and countries, particularly as regards the in-depth biological function and clinical translational research of this biomarker. |
| URI | http://hdl.handle.net/20.500.11897/435567 |
| ISSN | 1019-6439 |
| DOI | 10.3892/ijo.2015.3316 |
| Indexed | SCI(E) PubMed |
| Appears in Collections: | 北京肿瘤医院 |
